TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $7.80 Consensus PT from Analysts

Key Points

• TScan Therapeutics, Inc. (NASDAQ:TCRX) has received a consensus rating of "Buy" from five brokerages, with an average 1-year price target of $7.80.
• The company's recent earnings report indicated revenue of $3.08 million for the quarter, significantly exceeding the consensus estimate of $1.31 million.
• TScan Therapeutics is a clinical-stage biopharmaceutical company developing T cell receptor-engineered therapies for cancer, currently conducting Phase I trials for its lead product candidates.

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been assigned an average recommendation of "Buy" from the five brokerages that are covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have covered the stock in the last year is $7.80.

Several analysts recently issued reports on the stock. Wall Street Zen upgraded shares of TScan Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. Wedbush restated an "outperform" rating and issued a $7.00 price objective on shares of TScan Therapeutics in a report on Tuesday, August 12th. Finally, HC Wainwright reduced their price objective on shares of TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th.

TScan Therapeutics Stock Performance

TCRX stock traded down $0.05 during trading on Thursday, reaching $1.75. The company had a trading volume of 147,227 shares, compared to its average volume of 196,474. The firm has a 50-day simple moving average of $1.73 and a 200-day simple moving average of $1.62. The company has a market cap of $99.31 million, a price-to-earnings ratio of -1.61 and a beta of 1.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.06 and a current ratio of 7.06. TScan Therapeutics has a twelve month low of $1.02 and a twelve month high of $6.23.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter, hitting analysts' consensus estimates of ($0.28). The company had revenue of $3.08 million during the quarter, compared to analysts' expectations of $1.31 million. TScan Therapeutics had a negative net margin of 1,964.88% and a negative return on equity of 63.33%. As a group, sell-side analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current year.

Institutional Trading of TScan Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. ProShare Advisors LLC purchased a new stake in TScan Therapeutics during the fourth quarter worth about $40,000. Catalyst Funds Management Pty Ltd purchased a new stake in TScan Therapeutics during the second quarter worth about $26,000. Squarepoint Ops LLC acquired a new position in TScan Therapeutics in the fourth quarter valued at approximately $59,000. Wells Fargo & Company MN boosted its holdings in TScan Therapeutics by 41.1% in the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock valued at $59,000 after purchasing an additional 5,694 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of TScan Therapeutics in the second quarter valued at approximately $29,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.